358 related articles for article (PubMed ID: 28322294)
41. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
42. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Liu X; Men P; Wang Y; Zhai S; Liu G
Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
44. Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
Richard KR; Shelburne JS; Kirk JK
Clin Ther; 2011 Nov; 33(11):1609-29. PubMed ID: 22071236
[TBL] [Abstract][Full Text] [Related]
45. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172
[TBL] [Abstract][Full Text] [Related]
46. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.
Fei Y; Tsoi MF; Kumana CR; Cheung TT; Cheung BMY
Int J Cardiol; 2018 Mar; 254():291-296. PubMed ID: 29277321
[TBL] [Abstract][Full Text] [Related]
47. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
48. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
Yasuda T; Shimomura I
Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
[TBL] [Abstract][Full Text] [Related]
49. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.
Schott G; Martinez YV; Ediriweera de Silva RE; Renom-Guiteras A; Vögele A; Reeves D; Kunnamo I; Marttila-Vaara M; Sönnichsen A
BMC Geriatr; 2017 Oct; 17(Suppl 1):226. PubMed ID: 29047372
[TBL] [Abstract][Full Text] [Related]
50. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
51. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
[TBL] [Abstract][Full Text] [Related]
52. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
Green JB
Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
[TBL] [Abstract][Full Text] [Related]
53. Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Gong Y; Bai X; Zhang D; Yang X; Qin Z; Yang Y; Zhou Y; Meng J; Liu X
Lipids Health Dis; 2024 May; 23(1):157. PubMed ID: 38796440
[TBL] [Abstract][Full Text] [Related]
54. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.
Fu J; Zhu J; Hao Y; Guo C; Zhou Z
Sci Rep; 2016 Jul; 6():29104. PubMed ID: 27384445
[TBL] [Abstract][Full Text] [Related]
55. The Effects of Synbiotic Supplementation on Glucose Metabolism and Lipid Profiles in Patients with Diabetes: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Tabrizi R; Moosazadeh M; Lankarani KB; Akbari M; Heydari ST; Kolahdooz F; Asemi Z
Probiotics Antimicrob Proteins; 2018 Jun; 10(2):329-342. PubMed ID: 28677046
[TBL] [Abstract][Full Text] [Related]
56. Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.
Fujita K; Kaneko M; Narukawa M
Clin Drug Investig; 2017 Mar; 37(3):219-232. PubMed ID: 27848150
[TBL] [Abstract][Full Text] [Related]
57. Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease.
Davis H; Jones Briscoe V; Dumbadze S; Davis SN
Expert Opin Investig Drugs; 2019 Apr; 28(4):377-388. PubMed ID: 30848158
[TBL] [Abstract][Full Text] [Related]
58. Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis.
Lee S; Lee H; Kim Y; Kim E
Sci Rep; 2019 Sep; 9(1):13296. PubMed ID: 31527625
[TBL] [Abstract][Full Text] [Related]
59. DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Wang Q; Long M; Qu H; Shen R; Zhang R; Xu J; Xiong X; Wang H; Zheng H
J Diabetes Res; 2018; 2018():5308582. PubMed ID: 29507862
[TBL] [Abstract][Full Text] [Related]
60. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis.
Overbeek JA; Bakker M; van der Heijden AAWA; van Herk-Sukel MPP; Herings RMC; Nijpels G
Diabetes Metab Res Rev; 2018 Jul; 34(5):e3004. PubMed ID: 29573125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
